Articles related to BREAST CANCER

Publication: JAMA Oncology Design: An analysis of data from the I-SPY2 randomized clinical trial that included 938 women with breast cancer.Results: In this randomized clinical trial, the prognostic significance of RCB was consistent regardless of cancer subtype and treatment.

This Q&A with Dana Farber’s Dr. Rinath Jeselsohn centers on fulvestrant (Faslodex, AZ) and its current role in the management of breast cancer, as well as outlining the emerging selective estrogen receptor degraders (SERDs), their clinical trial data, potential for use, and whether the options will become the “backbone” of endocrine therapy in HER2-negative metastatic breast cancer.

In this comprehensive Journal of Clinical Oncology clinical review, the authors suggest that reexamination of breast cancer risk reduction strategies and clinical practice is needed. Prediction models, breast cancer mortality, prognostic categories, and the Women’s Health Initiative (WHI) randomized trials, dietary modification (DM) trial, hormone therapy trials, estrogen, and estrogen plus progestin trials are all discussed in great detail.

After diagnosis during a partial mastectomy, this patient’s estimated blood loss was 58 mL, causing anemia and requiring a red blood cell transfusion along with ventriculoperitoneal drain placement. With a substantive bleeding history before the diagnosis, what would you do next with this patient? Work her up for von Willebrand disease? Do a complete blood count test to look at platelet count, a peripheral smear to look at the morphology of the platelets, and a coagulation profile? Offer genetic testing for fibrinogen disorders? What would your next steps be? Read the full case presentation and expert opinion to see how your peers responded.

Trilaciclib (Cosela, G1 Therapeutics), a cyclin dependent kinase 4/6 inhibitor, is already approved in the United States to reduce frequency of chemotherapy-related bone marrow suppression among adults with extensive-stage small cell lung cancer. Now, the FDA has granted fast track designation to the drug for use in combo with chemo for treatment of locally advanced or metastatic TNBC.

Is there a benefit for patients who receive celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)–negative primary breast cancer? A report on the Randomized European Celecoxib Trial (REACT), a phase 3, randomized, double-blind study conducted in 160 centers across the UK and Germany testing two years of adjuvant celecoxib vs. placebo among 2,639 patients recruited between 2007 and 2012, with follow-up 10 years after treatment completion.